^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    IL7R-BCL2 fusion

    i
    Other names: IL7R, Interleukin 7 Receptor, Interleukin-7 Receptor Subunit Alpha, IL-7 Receptor Subunit Alpha, L-7R Subunit Alpha, CD127 Antigen, IL-7R-Alpha, Interleukin 7 Receptor Isoform H5-6, Interleukin 7 Receptor Alpha Chain, CDW127, CDw127, IL-7RA, CD127, IL7RA, ILRA, BCL2, Bcl-2, PPP1R50, B-cell CLL/lymphoma 2
    Entrez ID:
    596; 3575
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    over3years
    [VIRTUAL] Next generation sequencing of sarcomas: Response to crizotinib in two cases with MET amplification. (ASCO 2021)
    Several rare and novel fusions were identified; a sarcoma with TPM4-NTRK3 fusion responded to larotrectinib, while a sarcoma with PML-JAK1 fusion did not respond to ruxolitinib, and a sarcoma with IL7R-BCL2 fusion progressed on venetoclax . NGS profiling led to a targeted therapy with a clinical benefit rate of 12% in this cohort . NGS profiling led to a change in diagnosis in 5% of this cohort . Multi-institutional collaborations to track outcomes of matched therapy would help determine the utility of therapies in rare cancers and unusual alterations.
    Clinical • Next-generation sequencing • Tumor Mutational Burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • MET (MET proto-oncogene, receptor tyrosine kinase) • BCL2 (B-cell CLL/lymphoma 2) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • JAK1 (Janus Kinase 1) • IL7R (Interleukin 7 Receptor) • TPM4 (Tropomyosin 4)
    |
    TMB-H • NTRK3 fusion • MET amplification • IL7R-BCL2 fusion • PML-JAK1 fusion • TPM4-NTRK3 fusion • BCL2 fusion
    |
    Venclexta (venetoclax) • Xalkori (crizotinib) • Vitrakvi (larotrectinib) • Jakafi (ruxolitinib)